HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nicorette Gum Package Front In US Adds Initial, Zyrtec Labeling Gets ‘New’ For Limited Time

Executive Summary

Front panels for 34 SKUs for Haleon’s Nicorette 2- and 4-mg gum in approved to include a superimposed letter N; labeling approved for seven SKUs for Kenvue’s Zyrtec Allergy 5- and 10-mg tablets to include “new” for six months.

You may also be interested in...



US FDA Wants ‘Minor’ Labeling Changes For OTCs Available Through NDAs/ANDAs In Annual Reports

Fewer labeling changes submitted for OTC NDAs/ANDAs makes more time available for CDER reviews of other applications for OTC switches as well as non-minor labeling changes to nonprescription drugs plus far larger number of submissions for Rx drug approvals and labeling.

Newly On Its Own, Kenvue Still Emphasizes Traditional ‘Arsenal Of Tools’ To Deliver Results

During Kenvue’s first earnings briefing, CEO Thibaut Mongon touts adding products and extending lines but repeatedly references attention to fundamentals of manufacturing and marketing OTC drugs, personal and skin care lines and other consumer health products.

GSK Exits Consumer Health With Haleon Launch

The global market leader in consumer health is now Haleon following its separation from GSK after more than two years of planning.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel